Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, discusses the experiences of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) at the initial stages of treatment with lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, in a clinical trial setting. A quantitative analysis study, which invited patients with R/R LBCL from the TRANSCEND WORLD (NCT03484702) and PLATFORM (NCT03310619) trials, used interviews to investigate patients’ expectations and experiences at three time points: at screening, after leukapheresis, and up to 3 days after liso-cel infusion. The study found that overall perceptions were positive, with many finding the initial processes easier than first expected. Reported concerns lessened in subsequent interviews. While patients’ physical health remained stable or deteriorated from screening to post-infusion, over 90% of participants said they felt positive at interview 3. Interviews will continue to look at longer-term experiences. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.